» Articles » PMID: 7508683

Exuberant Endothelial Cell Growth and Elements of Inflammation Are Present in Plexiform Lesions of Pulmonary Hypertension

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1994 Feb 1
PMID 7508683
Citations 310
Authors
Affiliations
Soon will be listed here.
Abstract

The plexiform lesion in primary pulmonary hypertension is a glomeruloid structure forming channels in branches of the pulmonary artery. These lesions have been considered an abnormal growth of modified smooth muscle cells. We present immunohistochemical evidence in 10 cases of plexogenic pulmonary hypertension that the plexiform channels and the concentric obliterative arteriopathy associated with these channels represent abnormal growth of factor VIII-related antigen-positive endothelial cells. In addition, these cells strongly expressed vimentin, a growth- and differentiation-related intermediate filament. Morphologically and immunohistochemically, the lesions resembled the neovascularization associated with the brain tumor glioblastoma multiform. Furthermore, we noted an exclusively perivascular inflammatory cell infiltrate (but no vasculitis) in seven of the 10 cases with plexogenic arteriopathy composed of T cells, B cells, and macrophages. Our findings indicate that the plexiform lesion may result from a deregulated growth of endothelial cells. The presence of perivascular inflammatory cells suggested that cytokines and growth factors may further influence the development of the plexiform lesion.

Citing Articles

High-altitude pulmonary hypertension: a comprehensive review of mechanisms and management.

Yang X, Liu H, Wu X Clin Exp Med. 2025; 25(1):79.

PMID: 40063280 PMC: 11893705. DOI: 10.1007/s10238-025-01577-3.


PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis.

Xue Z, Han M, Sun T, Wu Y, Xing W, Mu F Theranostics. 2025; 15(2):745-765.

PMID: 39744686 PMC: 11671384. DOI: 10.7150/thno.102597.


Hypoxia-Induced Mitochondrial ROS and Function in Pulmonary Arterial Endothelial Cells.

Wang H, Song T, Reyes-Garcia J, Wang Y Cells. 2024; 13(21.

PMID: 39513914 PMC: 11545379. DOI: 10.3390/cells13211807.


Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies.

Tsai J, Malik S, Tjen-A-Looi S Life (Basel). 2024; 14(10).

PMID: 39459565 PMC: 11509317. DOI: 10.3390/life14101265.


Nanoparticle delivery of VEGF and SDF-1α as an approach for treatment of pulmonary arterial hypertension.

Guarino V, Wertheim B, Xiao W, Loscalzo J, Zhang Y Pulm Circ. 2024; 14(4):e12412.

PMID: 39380978 PMC: 11459680. DOI: 10.1002/pul2.12412.


References
1.
Gillespie M, Goldblum S, Cohen D, McClain C . Interleukin 1 bioactivity in the lungs of rats with monocrotaline-induced pulmonary hypertension. Proc Soc Exp Biol Med. 1988; 187(1):26-32. DOI: 10.3181/00379727-187-42632. View

2.
Balk A, Dingemans K, Wagenvoort C . The ultrastructure of the various forms of pulmonary arterial intimal fibrosis. Virchows Arch A Pathol Anat Histol. 1979; 382(2):139-50. DOI: 10.1007/BF01102870. View

3.
Ferrara N, Henzel W . Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989; 161(2):851-8. DOI: 10.1016/0006-291x(89)92678-8. View

4.
Wilson D, Segall H, Pan L, Dunston S . Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats. Microvasc Res. 1989; 38(1):57-80. DOI: 10.1016/0026-2862(89)90017-4. View

5.
Palevsky H, Schloo B, Pietra G, Weber K, Janicki J, Rubin E . Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation. 1989; 80(5):1207-21. DOI: 10.1161/01.cir.80.5.1207. View